Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice.

被引:14
作者
Saito S. [1 ]
Kasturi K. [1 ]
Bona C. [1 ]
机构
[1] Department of Microbiology, Mount Sinai School of Medicine, New York, NY
关键词
Scleroderma; Collagen Versus; Backcross Progeny; Tight Skin; Systemic Scleroderma;
D O I
10.1007/s11926-999-0022-4
中图分类号
学科分类号
摘要
Tight-skin (TSK) mouse, the experimental model for scleroderma, develops cutaneous hyperplasia and autoantibodies to scleroderma specific autoantigens. TSK syndrome is caused by a mutation on chromosome 2. Induction of cutaneous hyperplasia is due to intragenic duplication of exons 17 to 40 of fibrillin-1 gene, mapping close to TSK locus. The mutant mouse expresses a 14kb Fbn transcript in addition to 11kb wild-type transcript. Immunoprecipation analysis confirms that the mutant transcript is functional and codes for a 420kD fibrillin. The occurrence of TSK syndrome is independent of the presence of mature lymphocytes although splenic/bone marrow cells appear to be capable of transferring the disease in normal animals. Transgenic mice expressing mutant transgene develop mild skin thickness with associate biochemical changes but do not develop anti-topo I antibodies. Among the other factors that may contribute to the develop- ment of hyperplasia, collagen V seems to play an important role.
引用
收藏
页码:34 / 37
页数:3
相关论文
共 91 条
[1]  
Bona C(1994)Autoantibodies in scleroderma and tight skin mice Curr Opin Immunol 6 831-837
[2]  
Rothfield N(1982)Antibodies to collagen in scleroderma Arth Rheum. 25 552-531
[3]  
Mackel AM(1998)Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice Autoimmunity. 28 151-155
[4]  
DeLustro F(1986)Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils J Cell Biol 103 2499-2509
[5]  
Harpner FE(1991)Extracellular microfibrils are increased in localized and systemic scleroderma skin Lab Invest 64 791-798
[6]  
Murai C(1980)Bleomycin induced scleroderma J Rheum 7 654-659
[7]  
Saito S(1975)An approach to experimental scleroderma using urinary glycosaminoglycans from patients with systemic scleroderma Acta Dermatol Venerol 55 97-107
[8]  
Kasturi K(1995)The tight skin 2 mouse Arthritis Rheum. 38 1791-1798
[9]  
Sakai LY(1985)Murine graft-versus-host disease across minor barriers:Immunosupressive aspects of natural suppressor cells Immuno Rev 88 96-105
[10]  
Keene DR(1996)A high-resolution linkage map of tight skin 2 (Tsk2) locus: a mouse model for scleroderma (SSc) and other cutaneous fibrotic diseases Mammalian Genome 7 610-612